Solid Biosciences (SLDB) EBT (2017 - 2026)

Solid Biosciences has reported EBT for 10 years, with the latest figure at -$60.7 million in Q1 2026.

• Quarterly EBT fell 60.13% year-over-year to -$60.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$201.7 million (down 43.4% YoY) and the FY2025 annual result came in at -$359.7 million, down 43.35% from the prior year.
• EBT declined to -$60.7 million in Q1 2026 per SLDB's latest filing, from -$51.7 million in the prior quarter.
• Over five years, EBT peaked at -$20.6 million in Q3 2022 and troughed at -$196.6 million in Q4 2022.
• A 5-year average of -$43.7 million and a median of -$32.1 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2023 and 2024: EBT surged 87.45% in 2023, then sank 70.15% in 2024.
• Over 5 years, EBT stood at -$196.6 million in 2022, then soared by 87.45% to -$24.7 million in 2023, then tumbled by 70.15% to -$42.0 million in 2024, then declined by 23.27% to -$51.7 million in 2025, then declined by 17.28% to -$60.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$60.7 million, -$51.7 million, and -$47.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.